Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Drug Discov Ther ; 10(3): 177-80, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-27301711

RESUMO

Non-arteritic posterior ischemic optic neuropathy (NA-PION) is a disorder involving reduced blood flow to the retrobulbar portion of the optic nerve. This disorder usually develops acutely, and research has suggested that high-dose steroid therapy soon after the onset of visual loss can result in significant visual improvement. This treatment, however, is not universally successful. The addition of a potent vasodilator could help to restore ocular blood flow. This case report describes the use of prostaglandin E1 (PGE1), a powerful vasodilator of the microcirculation, to treat three separate episodes of NA-PION over five years in the same patient. A 68-year-old white male was first seen in June 2009 with NA-PION in the left eye, and the condition was treated with steroids and PGE1. The patient had a subsequent episode in July 2010 that was treated with steroids and PGE1 and another in May 2014 that was treated with PGE1 alone. Visual acuity improved from 4/10 to 11/10 in 2009, from 4/10 to 11/10 in 2010, and from 5/10 to 10/10 in 2014. No complications due to the use of PGE1 were noted. PGE1 should be considered as a treatment for NA-PION to immediately restore blood flow and potentially improve vision.


Assuntos
Alprostadil/efeitos adversos , Alprostadil/uso terapêutico , Neuropatia Óptica Isquêmica/induzido quimicamente , Vasodilatadores/efeitos adversos , Vasodilatadores/uso terapêutico , Idoso , Hemocromatose/complicações , Hemocromatose/genética , Humanos , Masculino , Microcirculação/efeitos dos fármacos , Neuropatia Óptica Isquêmica/diagnóstico por imagem , Artéria Retiniana/efeitos dos fármacos , Oclusão da Artéria Retiniana/tratamento farmacológico , Ultrassonografia Doppler em Cores , Acuidade Visual/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA